A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer.
A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer.
复制标题
amonafide、caracemide 和高三尖杉酯碱治疗晚期肾细胞癌患者的 II 期试验。
DOI：
10.1007/bf00180819
复制
发表时间：
1996
影响因子：
3.4
通讯作者：
Trump,DL
中科院分区：
文献类型：
--
作者：
Witte,RS;Hsieh,P;Elson,P;Oken,MM;Trump,DL
48 名先前未经治疗的晚期或不可切除肾癌的门诊患者接受了阿莫菲德（17 名患者）、caracemide（17 名患者）或高三尖杉酯碱（14 名患者）治疗。在任何治疗组中均未观察到客观反应。 Amonafide 和 caracemide 的耐受性良好，没有意外的毒性。高三尖杉酯碱组各有一名患者死于肺血栓栓塞和脓毒症，并伴有严重代谢性酸中毒。另外 4 名患者出现了 4 级并发症，包括骨髓抑制、神经功能障碍和呼吸衰竭。这些严重且意想不到的并发症导致高三尖杉酯碱组的研究提前终止。这些药物对于治疗晚期肾细胞癌没有活性。
Forty-eight previously untreated, ambulatory patients with advanced or unresectable renal carcinoma were treated with either amonafide (17 patients), caracemide (17 patients), or homoharringtonine (14 patients). No objective responses were observed in any of the treatment cohorts. Amonafide and caracemide were well tolerated with no unexpected toxicities. One patient each died of pulmonary thromboembolism and sepsis with severe metabolic acidosis on the homoharringtonine arm. An additional 4 patients experienced grade 4 complications including myelosuppression, neurologic dysfunction, and respiratory failure. These severe and unexpected complications caused early termination of accrual to the homoharringtonine arm of the study. These agents have no activity in the treatment of advanced renal cell carcinoma.